ArticleScientific reports2016
Hepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Applications of artificial intelligence (AI) in researches on non-alcoholic fatty liver disease(NAFLD) : A systematic review.Reviews in endocrine & metabolic disorders · 2022Pooled it
- Review
- Artificial Intelligence in Hepatocellular Carcinoma: Current Applications, Clinical Performance, and Barriers to Implementation.Journal of clinical medicine · 2026Review
- Time-restricted feeding combined with exercise improves hepatic and glycaemic metabolism in obese mice: A sex-dependent study.The Journal of physiology · 2025Article
- Serum and Liver Lipidome Following Empagliflozin Administration for Six Months in a Fast Food Diet Mouse Model.International journal of molecular sciences · 2025Article
- Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.International journal of molecular sciences · 2025Review
- The association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and non-alcoholic fatty liver disease in US adults: a cross-sectional study.Scientific reports · 2024Article
- Predicting Non-Alcoholic Steatohepatitis: A Lipidomics-Driven Machine Learning Approach.International journal of molecular sciences · 2024Article
- P2Y13 receptor deficiency favors adipose tissue lipolysis and worsens insulin resistance and fatty liver disease.JCI insight · 2024Article
- LipidSIM: Inferring mechanistic lipid biosynthesis perturbations from lipidomics with a flexible, low-parameter, Markov modeling framework.Metabolic engineering · 2024Article
- Plasma Lipids Profile in the Prediction of Non-Alcoholic Steatohepatitis in Adults: A Case-Control Study.International journal of molecular sciences · 2023Article
- Myristic Acid Supplementation Aggravates High Fat Diet-Induced Adipose Inflammation and Systemic Insulin Resistance in Mice.Biomolecules · 2022Article
- Artificial intelligence in the detection, characterisation and prediction of hepatocellular carcinoma: a narrative review.Translational gastroenterology and hepatology · 2022Review
- Age- and Diet-Dependent Changes in Hepatic Lipidomic Profiles of Phospholipids in Male Mice: Age Acceleration in Cyp2b-Null Mice.Journal of lipids · 2022Article
- Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma.Chinese medical journal · 2021Review
- Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study.Free radical biology & medicine · 2021Article
- Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma.Biomedicines · 2021Review
- HR-MS Based Untargeted Lipidomics Reveals Characteristic Lipid Signatures of Wilson's Disease.Frontiers in pharmacology · 2021Article
- Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver.International journal of molecular sciences · 2020Article
- The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease.Metabolism: clinical and experimental · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver (NAFL) is a precursor of nonalcoholic steatohepatitis (NASH), a condition that may progress to cirrhosis and hepatocellular carcinoma. Markers for diagnosis of NASH are still lacking. We have investigated lipid markers using mouse models that developed NAFL when fed with high fat diet (HFD) or NASH when fed using methionine choline deficient diet (MCDD). We have performed a comprehensive lipidomic analysis on liver tissues as well as on sera from mice fed HFD (n = 5), MCDD (n = 5) or normal diet as controls (n = 10). Machine learning approach based on prediction analysis of microarrays followed by random forests allowed identifying 21 lipids out of 149 in the liver and 14 lipids out of 155 in the serum discriminating mice fed MCDD from HFD or controls. In conclusion, the global approach implemented allowed characterizing lipid signatures specific to NASH in both liver and serum from animal models. This opens new avenue for investigating early and non-invasive lipid markers for diagnosis of NASH in human.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.